Form 4: Elanco Animal Health Executive Shiv O'Neill Reports Stock and Option Grants

Shiv O'Neill, GC AND CORP SEC of Elanco Animal Health, reports the acquisition of restricted stock units and stock options.

Summary

• On March 3, 2025, Shiv O'Neill, GC AND CORP SEC of Elanco Animal Health Inc, reported transactions involving Elanco's common stock and employee stock options.
• O'Neill acquired 30,947 shares of common stock through restricted stock units and disposed of 0 shares.
• These restricted stock units vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028.
• Additionally, O'Neill acquired 64,936 employee stock options with an exercise price of $11.31.
• These options also vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028, and expire on March 3, 2035.
• Following these transactions, O'Neill directly owns 53,917 shares of Elanco common stock and 64,936 employee stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of restricted stock units and stock options to a key executive aligns their interests with the long-term performance of the company.
• The vesting schedule of the grants (one-third each year for three years) encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock grants suggests an expectation of continued employment and contribution from the executive.

Industry Context

Stock and option grants are a common practice in the animal health industry to incentivize and retain key executives. These grants align the executive's interests with those of the shareholders, encouraging them to work towards increasing the company's value.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices among publicly traded animal health companies such as Zoetis and IDEXX Laboratories.
• The vesting schedules and exercise prices are typically structured to align with industry norms for executive compensation.
• The size of the grant is likely determined by Elanco's compensation committee based on factors such as the executive's role, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value.
• Employees: The grants may serve as a positive signal regarding the company's commitment to its leadership.
• Executive: The grants provide an incentive for continued service and performance.

Key Dates